EVKEEZA

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug EVKEEZA contains one active pharmaceutical ingredient (API):

1	Evinacumab UNII T8B2ORP1DW - EVINACUMAB
	Evinacumab is a recombinant human monoclonal antibody, which specifically binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab blockade of ANGPTL3 lowers TG and HDL-C by releasing LPL and EL activities from ANGPTL3 inhibition, respectively.
	Read more about Evinacumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EVKEEZA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AX	Other lipid modifying agents	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain
Discover more medicines within C10AX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1852545, 1852556
ES	Centro de información online de medicamentos de la AEMPS	1211551001
FR	Base de données publique des médicaments	64336907
IT	Agenzia del Farmaco	049619012, 049619024
LT	Valstybinė vaistų kontrolės tarnyba	1092848, 1092849
PL	Rejestru Produktów Leczniczych	100455264
US	FDA, National Drug Code	61755-010, 61755-013